How much profit has HLB Life Science Co made this year?
HLB Life Science Co has made -5.98 B KRW this year.
HLB Life Science Co Net Income 2024
HLB Life Science Co Net Income
-5.98 B KRW
Ticker
067630.KQ
ISIN
KR7067630004
In 2024, HLB Life Science Co's profit amounted to -5.98 B KRW, a -88.98% increase from the -54.28 B KRW profit recorded in the previous year.
The HLB Life Science Co Net Income history
| YEAR | NET INCOME (undefined KRW) |
|---|---|
| 2023 | -5.98 |
| 2022 | -54.28 |
| 2021 | -49.15 |
| 2020 | -55.8 |
| 2019 | -7.61 |
| 2018 | -3.07 |
| 2017 | 7.76 |
| 2016 | -1.25 |
| 2015 | -17.04 |
| 2014 | 1.4 |
| 2013 | -4.07 |
| 2012 | -8.35 |
| 2011 | -4.02 |
HLB Life Science Co Revenue, EBIT, Net Income KR7067630004 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into HLB Life Science Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by HLB Life Science Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects HLB Life Science Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of HLB Life Science Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into HLB Life Science Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing HLB Life Science Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on HLB Life Science Co’s growth potential.
HLB Life Science Co Revenue, EBIT and net profit per share
| Date | HLB Life Science Co Revenue | HLB Life Science Co EBIT | HLB Life Science Co Net Income |
|---|---|---|---|
| 2023 | 97.99 B undefined | -24.53 B undefined | -5.98 B undefined |
| 2022 | 99.59 B undefined | -20.16 B undefined | -54.28 B undefined |
| 2021 | 53.49 B undefined | -18.48 B undefined | -49.15 B undefined |
| 2020 | 91.8 B undefined | -8.07 B undefined | -55.8 B undefined |
| 2019 | 114.02 B undefined | -4.48 B undefined | -7.61 B undefined |
| 2018 | 102.48 B undefined | -7.96 B undefined | -3.07 B undefined |
| 2017 | 106.45 B undefined | 989 M undefined | 7.76 B undefined |
| 2016 | 42.23 B undefined | -1.4 B undefined | -1.25 B undefined |
| 2015 | 27.32 B undefined | -9.7 B undefined | -17.04 B undefined |
| 2014 | 36.56 B undefined | 1.45 B undefined | 1.4 B undefined |
| 2013 | 19.96 B undefined | -3.2 B undefined | -4.07 B undefined |
| 2012 | 9 B undefined | -4.67 B undefined | -8.35 B undefined |
| 2011 | 40.95 B undefined | -2.19 B undefined | -4.02 B undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2011 | 40.95 B KRW | -2.19 B KRW | -4.02 B KRW |
| 2012 | 9 B KRW | -4.67 B KRW | -8.35 B KRW |
| 2013 | 19.96 B KRW | -3.2 B KRW | -4.07 B KRW |
| 2014 | 36.56 B KRW | 1.45 B KRW | 1.4 B KRW |
| 2015 | 27.32 B KRW | -9.7 B KRW | -17.04 B KRW |
| 2016 | 42.23 B KRW | -1.4 B KRW | -1.25 B KRW |
| 2017 | 106.45 B KRW | 989 M KRW | 7.76 B KRW |
| 2018 | 102.48 B KRW | -7.96 B KRW | -3.07 B KRW |
| 2019 | 114.02 B KRW | -4.48 B KRW | -7.61 B KRW |
| 2020 | 91.8 B KRW | -8.07 B KRW | -55.8 B KRW |
| 2021 | 53.49 B KRW | -18.48 B KRW | -49.15 B KRW |
| 2022 | 99.59 B KRW | -20.16 B KRW | -54.28 B KRW |
| 2023 | 97.99 B KRW | -24.53 B KRW | -5.98 B KRW |
HLB Life Science Co stock margins KR7067630004 ·
The HLB Life Science Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of HLB Life Science Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for HLB Life Science Co.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the HLB Life Science Co's sales revenue. A higher gross margin percentage indicates that the HLB Life Science Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the HLB Life Science Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the HLB Life Science Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the HLB Life Science Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the HLB Life Science Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the HLB Life Science Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
HLB Life Science Co Margin History
| HLB Life Science Co Gross margin | HLB Life Science Co Profit margin | HLB Life Science Co EBIT margin | HLB Life Science Co Profit margin |
|---|---|---|---|
| 2023 | -0.76 % | -25.04 % | -6.11 % |
| 2022 | -3.06 % | -20.24 % | -54.5 % |
| 2021 | -10.35 % | -34.55 % | -91.88 % |
| 2020 | 2.53 % | -8.79 % | -60.78 % |
| 2019 | 6.67 % | -3.93 % | -6.67 % |
| 2018 | 4.56 % | -7.77 % | -2.99 % |
| 2017 | 5.09 % | 0.93 % | 7.29 % |
| 2016 | 7.82 % | -3.31 % | -2.96 % |
| 2015 | -16.43 % | -35.49 % | -62.37 % |
| 2014 | 14.31 % | 3.97 % | 3.84 % |
| 2013 | 1.05 % | -16.04 % | -20.41 % |
| 2012 | 3.5 % | -51.94 % | -92.8 % |
| 2011 | 5.33 % | -5.34 % | -9.82 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2011 | 5.33 % | -5.34 % | -9.82 % |
| 2012 | 3.5 % | -51.94 % | -92.8 % |
| 2013 | 1.05 % | -16.04 % | -20.41 % |
| 2014 | 14.31 % | 3.97 % | 3.84 % |
| 2015 | -16.43 % | -35.49 % | -62.37 % |
| 2016 | 7.82 % | -3.31 % | -2.96 % |
| 2017 | 5.09 % | 0.93 % | 7.29 % |
| 2018 | 4.56 % | -7.77 % | -2.99 % |
| 2019 | 6.67 % | -3.93 % | -6.67 % |
| 2020 | 2.53 % | -8.79 % | -60.78 % |
| 2021 | -10.35 % | -34.55 % | -91.88 % |
| 2022 | -3.06 % | -20.24 % | -54.5 % |
| 2023 | -0.76 % | -25.04 % | -6.11 % |
HLB Life Science Co Aktienanalyse
What does HLB Life Science Co do?
HLB Life Science Co., Ltd. is a leading company in the research, development, and production of biotechnological and pharmaceutical products. The company was founded in 2015 in Seoul, South Korea. Due to the founders' extensive experience in the field of life science and biotechnology, HLB Life Science has quickly established itself as a key player in the industry. HLB Life Science's business model is based on the development and production of innovative biotechnological and pharmaceutical products, as well as collaboration with other companies and research institutions. The aim is to improve people's quality of life by providing effective and safe medications and therapies. The company is divided into various divisions. The Biopharmaceuticals division includes the development and production of biotechnological products such as antibodies, proteins, vaccines, and diagnostics. The Pharmaceuticals division develops and produces advanced drugs in the field of oncology, immunology, and neurology. The Clinical Research Services division offers contract research services in the field of clinical studies to test the effectiveness and safety of drugs. In addition, HLB Life Science Co., Ltd. is also active in the Nutra-Pharmaceuticals division, specializing in the development and production of dietary supplements. HLB Life Science offers various products tailored to the needs of patients. In the field of Biopharmaceuticals, for example, the company produces antibodies and proteins for the treatment of cancer, inflammatory diseases, and infections. Another innovative product is a fully humanized antibody against the hepatitis B virus, which is one of the most common liver diseases. In the Pharmaceuticals field, HLB Life Science offers innovative drugs for the treatment of cancer, autoimmune diseases, and neurological disorders. In the Nutra-Pharmaceuticals field, the company offers dietary supplements based on natural ingredients that can strengthen the immune system. HLB Life Science Co., Ltd. is known in the industry for its innovative strength and excellent research results. The company places great emphasis on continuous research and development to develop innovative products and continuously improve existing products. Due to their outstanding products and services, HLB Life Science has already exported to various countries worldwide and has thus played a significant role in the global market. Looking to the future, HLB Life Science Co., Ltd. continues to focus on innovative research and development, as well as close collaboration with universities and research institutions. The company aims to improve people's health and well-being through effective and safe medications and therapies. HLB Life Science Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding HLB Life Science Co's Profit Margins
The profit margins of HLB Life Science Co represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of HLB Life Science Co's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating HLB Life Science Co's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
HLB Life Science Co's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When HLB Life Science Co’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about HLB Life Science Co stock
How has the profit developed compared to last year?
The profit has increased by -88.98% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does HLB Life Science Co publish its earnings?
HLB Life Science Co publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of HLB Life Science Co?
The profits of HLB Life Science Co are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of HLB Life Science Co?
You can learn more about the earnings of HLB Life Science Co by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does HLB Life Science Co pay?
Over the past 12 months, HLB Life Science Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, HLB Life Science Co is expected to pay a dividend of 0 KRW.
What is the dividend yield of HLB Life Science Co?
The current dividend yield of HLB Life Science Co is .
When does HLB Life Science Co pay dividends?
HLB Life Science Co pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of HLB Life Science Co?
HLB Life Science Co paid dividends every year for the past 0 years.
What is the dividend of HLB Life Science Co?
For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.
In which sector is HLB Life Science Co located?
HLB Life Science Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von HLB Life Science Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of HLB Life Science Co from 8/7/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 8/7/2024.
When did HLB Life Science Co pay the last dividend?
The last dividend was paid out on 8/7/2024.
What was the dividend of HLB Life Science Co in the year 2023?
In the year 2023, HLB Life Science Co distributed 0 KRW as dividends.
In which currency does HLB Life Science Co pay out the dividend?
The dividends of HLB Life Science Co are distributed in KRW.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von HLB Life Science Co
Our stock analysis for HLB Life Science Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of HLB Life Science Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- HLB Life Science Co Revenue
- HLB Life Science Co Net Income
- HLB Life Science Co P/E
- HLB Life Science Co P/S
- HLB Life Science Co EBIT
- HLB Life Science Co Dividend
- HLB Life Science Co Stocks
- HLB Life Science Co Market capitalization
- HLB Life Science Co Debt
- HLB Life Science Co Liabilities
- HLB Life Science Co Equity
- HLB Life Science Co AAQS
- HLB Life Science Co Employees
- HLB Life Science Co ROE
- HLB Life Science Co ROA
- HLB Life Science Co ROCE